camrelizumab + apatinib + fluzoparib

Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor. Apatinib is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis. Fluzoparib is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair in cancer cells with homologous recombination deficiency. The combination of these three agents aims to enhance antitumor efficacy by simultaneously promoting immune-mediated tumor cell killing, inhibiting tumor angiogenesis, and exploiting defects in DNA repair pathways. This regimen has been investigated primarily for advanced solid tumors such as triple-negative breast cancer and hepatocellular carcinoma[1][2][3][4].

Other names

SHR-1210 + apatinib + fluzoparib